ID
45707
Description
Principal Investigator: John S. Witte, PhD, University of California, San Francisco, CA, USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001221 A genome-wide association study (GWAS) of prostate cancer (PCa) was conducted in Kaiser Permanente (KP) Northern California health plan members (7,783 cases, 38,595 controls; 80.3% non-Hispanic white, 4.9% African-American, 7.0% East Asian, and 7.8% Latino) [PMID: 26034056]. The data for these members were drawn from three KP cohort studies: Research Program in Genes, Environment and Health (RPGEH) ProHealth, and California Men's Health Study (CMHS) (described further under Study History). Four custom arrays were designed for genotyping, one for each of the four major race-ethnicity groups in the RPGEH cohort: African Americans, East Asians, Latinos, and Non-Hispanic Whites. The number of SNPs and SNP content varied by array, with SNP content designed to maximize the genome-wide coverage of low frequency and more common variants specific to the different race-ethnicity groups, including newly identified SNPs from sequencing projects, and SNPs with established associations with disease phenotypes and risk factors [PMIDs: 21565264, 21903159]. Within the total study cohort, n=34,736 completed a consent which permitted deposition of data to NIH. Genotyping followed the same general procedure described in [PMIDs: 26092718, plus additional quality control (QC) steps for the additional men, in order to control for potential batch and kit effects, described in [PMID: 26034056. Briefly, we first repeated the filters described in [PMID: 26092718] for all four arrays (EUR, LAT, EAS, AFR). Then, on an array-wise basis, we removed SNPs with MAF0.01, with a call rate95%, or with Hardy-Weinberg Equilibrium (HWE) p-value in homogeneous groups1x10ˆ-5. Furthermore, on the EUR array, to adjust for potential kit effect, we conducted a GWAS of kit, and removed those kit associated SNPs with p1x10ˆ-6; we also re-genotyped each of the new samples (those not genotyped with the original GERA data) with some of the original GERA data, and removed SNPs with 13/1,268 (1%) mismatches. For the AFR array, to adjust potential plate batch issues, we conducted a GWAS of whether an individual was in the original GERA data vs. in the newly genotyped data and removed those batch-associated SNPs with p0.05 (we used a stronger threshold than that used for the EUR array because there were fewer individuals on the AFR array); we also re-genotyped each of the new samples with the original GERA data and removed SNPs with 2/78 (2.6%). After the QC described above, imputation was performed as described in [PMID: 26034056]. Imputation was performed on an array-wise basis, pre-phasing with SHAPE-IT v2.5 [PMID: 22138821], and imputing from the 1000 Genomes Project October 2014 release as a cosmopolitan reference panel with IMPUTE2 [PMID: 22384356]. In addition to the GWAS described above, a nested exome-wide association study (EWAS) of PCa was also conducted (7,489 cases, 7,323 controls; 78% non-Hispanic white, 9% African-American, 3% East Asian, 6% Latino, 4% Other). A custom EWAS array primarily focused on rare variants was designed for genotyping that complemented the GWAS arrays [PMID: 26034056]. The EWAS array content included missense and loss-of-function mutations, and rare exonic mutations from The Cancer Genome Atlas (TCGA) and dbGaP prostate cancer tumor exomes [PMID: 26544944; PMID: 26544944]. Much of the EWAS array design content overlapped with the probesets on the UK Biobank Affymetrix Axiom array [PMID: 30305743]. Genotyping and QC steps taken to filter out samples exhibiting low quality and variants with low call rates are described in Emami et al., 2020 [biorXiv]. The resulting EWAS array genotypes are provided here.
Lien
Mots-clés
Versions (1)
- 16/05/2023 16/05/2023 - Chiara Middel
Détendeur de droits
John S. Witte, PhD, University of California, San Francisco, CA, USA
Téléchargé le
16 mai 2023
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs001221 ProHealth: Kaiser Permanente GWAS of Prostate Cancer
Subject ID, sex, race, affection status, age, BMI, Gleason Summary Score, histologic grading and differentiation, and SEER general summary stage of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, source subject ID, and consent group of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- Subject ID, sex, monozygous twins, family ID, mother ID, father ID, and sex of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- Subject ID, array, African Principal Component, East Asian Principal Component, European Principal Component, and Latin Principal Component of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- Subject ID, sex, race, affection status, age, BMI, Gleason Summary Score, histologic grading and differentiation, and SEER general summary stage of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- Sample ID, package, analyte type, body site where sample was collected, tumor status of sample, and Reagent Kit of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
Similar models
Subject ID, sex, race, affection status, age, BMI, Gleason Summary Score, histologic grading and differentiation, and SEER general summary stage of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, source subject ID, and consent group of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- Subject ID, sex, monozygous twins, family ID, mother ID, father ID, and sex of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- Subject ID, array, African Principal Component, East Asian Principal Component, European Principal Component, and Latin Principal Component of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- Subject ID, sex, race, affection status, age, BMI, Gleason Summary Score, histologic grading and differentiation, and SEER general summary stage of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
- Sample ID, package, analyte type, body site where sample was collected, tumor status of sample, and Reagent Kit of participants with or without prostate cancer and involved in the "ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate Cancer" project.
C2348585 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,2])
C1302413 (UMLS CUI [1,2])
C1302413 (UMLS CUI [1,2])
C0681906 (UMLS CUI [1,2])
C1698493 (UMLS CUI [1,2])
C2945687 (UMLS CUI [1,2])
C0332326 (UMLS CUI [1,2])
Aucun commentaire